Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN)

$323.86 +8.04 (+2.55 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$323.86
Today's Range$315.16 - $323.90
52-Week Range$313.53 - $543.55
Volume676,026 shs
Average Volume1.28 million shs
Market Capitalization$34.01 billion
P/E Ratio31.38
Dividend YieldN/A
Beta1.47

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Debt-to-Equity Ratio0.11%
Current Ratio3.82%
Quick Ratio3.18%

Price-To-Earnings

Trailing P/E Ratio31.3818133544703
Forward P/E Ratio16.87
P/E Growth0.99

Sales & Book Value

Annual Sales$5.87 billion
Price / Sales5.94
Cash Flow$16.27 per share
Price / Cash19.91
Book Value$57.05 per share
Price / Book5.68

Profitability

Trailing EPS$10.32
Net Income$1.20 billion
Net Margins20.41%
Return on Equity28.48%
Return on Assets19.26%

Miscellaneous

Employees6,200
Outstanding Shares107,700,000

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its quarterly earnings data on Thursday, February, 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.18 by $1.05. The biopharmaceutical company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company's revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.04 earnings per share. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2018?

25 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their predictions range from $356.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $455.13 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea sales. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales in 2018. The action date set by the FDA is Aug 11, 2018. The approval of new drugs like Kevzara and Dupixent provides a significant boost. Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. Kevzara is also expected to pick up further. Even though sales of Praluent have failed to impress to date, we expect the same to gain traction as the year progresses. A potential approval of PD-1 antibody cemiplimab, in advanced cutaneous squamous cell carcinoma will further boost prospects. However, shares of the company have underperformed the industry in the last 12 months." (2/16/2018)
  • 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018)
  • 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board (Age 87)
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director (Age 64)
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance (Age 53)
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply (Age 44)
  • Neil Stahl Ph.D., Executive Vice President - Research and Development (Age 60)
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary (Age 58)
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation (Age 46)
  • Marion McCourt, Senior Vice President and Head of Commercial (Age 57)
  • Peter Powchik M.D., Senior Vice President - Clinical Development (Age 60)
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director (Age 57)

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SANOFI (22.60%), BlackRock Inc. (5.60%), Sands Capital Management LLC (2.38%), Polen Capital Management LLC (1.29%), Geode Capital Management LLC (0.82%) and American Century Companies Inc. (0.82%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, TIAA CREF Investment Management LLC, BlackRock Inc., Assenagon Asset Management S.A., Sands Capital Management LLC, Teachers Advisors LLC, Old Mutual Global Investors UK Ltd. and American Century Companies Inc.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Advisers LP, HealthCor Management L.P., Millennium Management LLC, UBS Asset Management Americas Inc., Bank of Montreal Can, ADAMCAPITAL Gestao de Recursos Ltda. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $323.86.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $34.01 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $10.32 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


MarketBeat Community Rating for Regeneron Pharmaceuticals (REGN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  1,023 (Vote Outperform)
Underperform Votes:  807 (Vote Underperform)
Total Votes:  1,830
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regeneron Pharmaceuticals (NASDAQ:REGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.322.362.382.40
Ratings Breakdown: 1 Sell Rating(s)
15 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
14 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
14 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
13 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $455.13$471.39$475.22$497.55
Price Target Upside: 40.89% upside23.49% upside23.48% upside3.95% upside

Regeneron Pharmaceuticals (NASDAQ:REGN) Consensus Price Target History

Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Canaccord GenuityDowngradeBuy -> Hold$522.00 -> $356.00MediumView Rating Details
2/13/2018BTIG ResearchReiterated RatingHoldHighView Rating Details
2/9/2018SunTrust BanksSet Price TargetHold$430.00LowView Rating Details
2/9/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$401.00 -> $415.00HighView Rating Details
2/9/2018Leerink SwannLower Price TargetOutperform -> Outperform$568.00 -> $502.00HighView Rating Details
2/9/2018Robert W. BairdUpgradeNeutral -> OutperformHighView Rating Details
2/9/2018GuggenheimSet Price TargetBuy$530.00HighView Rating Details
2/8/2018Jefferies GroupReiterated RatingNeutral -> Hold$380.00HighView Rating Details
2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$398.00 -> $444.00LowView Rating Details
2/7/2018Credit Suisse GroupSet Price TargetBuy$440.00HighView Rating Details
2/7/2018CowenReiterated RatingHold$450.00HighView Rating Details
1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral -> Neutral$455.00 -> $457.00LowView Rating Details
1/9/2018CitigroupReiterated RatingNeutral -> Neutral$380.00 -> $388.00HighView Rating Details
12/28/2017ArgusLower Price TargetPositive -> Buy$540.00 -> $470.00LowView Rating Details
12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00LowView Rating Details
12/12/2017Deutsche BankInitiated CoverageHold$397.00MediumView Rating Details
11/16/2017Evercore ISILower Price TargetOutperform$605.00 -> $445.00N/AView Rating Details
11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/AView Rating Details
10/20/2017BarclaysDowngradeEqual Weight -> Underweight$450.00 -> $395.00N/AView Rating Details
9/27/2017OppenheimerReiterated RatingHoldLowView Rating Details
9/6/2017Raymond James FinancialReiterated RatingOutperform -> Outperform$566.00LowView Rating Details
8/9/2017Goldman Sachs GroupReiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
7/21/2017Bank of AmericaReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings History and Estimates Chart

Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ REGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018$4.17N/AView Earnings Details
2/8/2018Q4 2017$4.18$5.23$1.50 billion$1.58 billionViewN/AView Earnings Details
11/8/2017Q3 2017$3.83$3.99$1.45 billion$1.50 billionViewN/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.75)($0.68)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
5/3/2011Q1 2011($0.38)($0.49)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.32)($0.17)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.34)($0.41)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.38)($0.31)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.49)($0.38)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.34)($0.46)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.23)($0.01)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.28)($0.19)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.29)($0.22)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.30)($0.40)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.32)($0.27)ViewN/AView Earnings Details
7/31/2008Q2 2008($0.35)($0.22)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.34)($0.15)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.46)($0.19)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings Estimates

Current Year EPS Consensus Estimate: $19.2 EPS
Next Year EPS Consensus Estimate: $20.07 EPS

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 64.67%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Joseph L GoldsteinDirectorSell1,000$325.60$325,600.00View SEC Filing  
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.0011,000View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.8010,099View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.3410,099View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.619,099View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.609,099View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24363,638View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65329,543View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00329,543View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62329,543View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.949,099View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.989,193View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.3043,950View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.003,000View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.9372,043View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.1544,245View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.0014,000View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.8828,477View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30414,156View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.003,000View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.001,000View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.0012,000View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.0036,500View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.0015,125View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.0015,125View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.0040,500View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.0111,381View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.0013,000View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.0016,000View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.326,866View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44500,000View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00332,880View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.4522,029View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98351,851View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28543,348View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.009,000View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.1715,441View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.009,000View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.0014,662View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.0014,662View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.0563,102View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.5863,102View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.001,000View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.1615,600View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.2020,029View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.8424,391View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.711,068,343View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.002,000View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.5069,960View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.3625,447View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.9320,742View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00112,772View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.003,000View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.8342,087View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.1665,759View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.0910,736View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.0016,644View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.004,000View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regeneron Pharmaceuticals (NASDAQ REGN) News Headlines

Source:
DateHeadline
Some Thoughts On The Continued Negative Media For Regeneron - Seeking AlphaSome Thoughts On The Continued Negative Media For Regeneron - Seeking Alpha
seekingalpha.com - February 23 at 3:44 PM
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
finance.yahoo.com - February 23 at 10:45 AM
Taking Stock of Regeneron Pharmaceuticals’ Marketed ProductsTaking Stock of Regeneron Pharmaceuticals’ Marketed Products
finance.yahoo.com - February 22 at 3:47 PM
Regeneron Pharmaceuticals’ Kevzara, Arcalyst, and ZaltrapRegeneron Pharmaceuticals’ Kevzara, Arcalyst, and Zaltrap
finance.yahoo.com - February 22 at 3:47 PM
Analyst Ratings for Regeneron Pharmaceuticals and Its PeersAnalyst Ratings for Regeneron Pharmaceuticals and Its Peers
finance.yahoo.com - February 22 at 3:47 PM
A Look at Regeneron Pharmaceuticals’ Product PipelineA Look at Regeneron Pharmaceuticals’ Product Pipeline
finance.yahoo.com - February 22 at 3:47 PM
Regeneron Pharmaceuticals and Its Financial PerformanceRegeneron Pharmaceuticals and Its Financial Performance
finance.yahoo.com - February 22 at 3:47 PM
Benzingas Top Upgrades, Downgrades For February 21, 2018 - BenzingaBenzinga's Top Upgrades, Downgrades For February 21, 2018 - Benzinga
www.benzinga.com - February 21 at 3:46 PM
Regenerons Eylea Has Mysterious Rise in Side Effect ReportsRegeneron's Eylea Has Mysterious Rise in Side Effect Reports
finance.yahoo.com - February 21 at 11:24 AM
Regeneron shares slip after Canaccord downgrades stock, slashes price target 32%Regeneron shares slip after Canaccord downgrades stock, slashes price target 32%
finance.yahoo.com - February 21 at 11:24 AM
Novavax (NVAX) in Focus: Stock Moves 8.3% HigherNovavax (NVAX) in Focus: Stock Moves 8.3% Higher
finance.yahoo.com - February 20 at 9:56 AM
Regeneron Annual Report, Earnings Forecast And Stock ValuationRegeneron Annual Report, Earnings Forecast And Stock Valuation
seekingalpha.com - February 19 at 9:56 AM
Zacks: Brokerages Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Announce Quarterly Sales of $1.54 BillionZacks: Brokerages Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Announce Quarterly Sales of $1.54 Billion
www.americanbankingnews.com - February 18 at 2:54 AM
$4.50 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter$4.50 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
www.americanbankingnews.com - February 16 at 5:10 PM
Regeneron Pharmaceuticals (REGN) Rating Increased to Strong-Buy at Zacks Investment ResearchRegeneron Pharmaceuticals (REGN) Rating Increased to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - February 16 at 10:12 AM
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol DrugsThe Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
finance.yahoo.com - February 15 at 3:46 PM
Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of CommercialRegeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial
finance.yahoo.com - February 14 at 3:21 PM
Regeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of "Hold" from BrokeragesRegeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 7:30 PM
Regeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in StockRegeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in Stock
www.americanbankingnews.com - February 13 at 6:28 PM
3 Biotech Stocks Facing Steep Declines3 Biotech Stocks Facing Steep Declines
finance.yahoo.com - February 13 at 3:18 PM
Stocks Up, These Groups Smoke Indexes; Buy This Bitcoin Fund Or Wait?Stocks Up, These Groups Smoke Indexes; Buy This Bitcoin Fund Or Wait?
finance.yahoo.com - February 13 at 3:18 PM
BTIG Research Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)BTIG Research Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)
www.americanbankingnews.com - February 13 at 11:32 AM
Handling Your Finances at Any Age: Cramers Mad Money Recap (Monday 2/12/18)Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)
finance.yahoo.com - February 13 at 5:51 AM
Regeneron - Levels To Regenerate? - Seeking AlphaRegeneron - Levels To Regenerate? - Seeking Alpha
seekingalpha.com - February 11 at 3:22 PM
Regeneron Pharmaceuticals (REGN) PT Set at $530.00 by GuggenheimRegeneron Pharmaceuticals (REGN) PT Set at $530.00 by Guggenheim
www.americanbankingnews.com - February 11 at 12:42 AM
Regeneron Pharmaceuticals (REGN) Upgraded by Robert W. Baird to OutperformRegeneron Pharmaceuticals (REGN) Upgraded by Robert W. Baird to Outperform
www.americanbankingnews.com - February 10 at 10:54 PM
Should You Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) To Continue Delivering An ROE Of 24.25%?Should You Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) To Continue Delivering An ROE Of 24.25%?
finance.yahoo.com - February 10 at 5:46 AM
Leerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00Leerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00
www.americanbankingnews.com - February 9 at 10:36 PM
Regeneron Pharmaceuticals (REGN) Price Target Raised to $415.00Regeneron Pharmaceuticals (REGN) Price Target Raised to $415.00
www.americanbankingnews.com - February 9 at 6:10 PM
Regeneron Pharmaceuticals (REGN) PT Set at $430.00 by SunTrust BanksRegeneron Pharmaceuticals (REGN) PT Set at $430.00 by SunTrust Banks
www.americanbankingnews.com - February 9 at 4:38 PM
Updating The Bullish Case For Regeneron As The Stock Drops - Seeking AlphaUpdating The Bullish Case For Regeneron As The Stock Drops - Seeking Alpha
seekingalpha.com - February 9 at 3:24 PM
Analyst: Regeneron Is Undervalued By The StreetAnalyst: Regeneron Is Undervalued By The Street
finance.yahoo.com - February 9 at 3:24 PM
Commit To Buy Regeneron Pharmaceuticals At $200, Earn 4.5% Using Options - NasdaqCommit To Buy Regeneron Pharmaceuticals At $200, Earn 4.5% Using Options - Nasdaq
www.nasdaq.com - February 9 at 5:49 AM
Regeneron Pharmaceuticals (REGN) "Hold" Rating Reaffirmed at Jefferies GroupRegeneron Pharmaceuticals' (REGN) "Hold" Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - February 8 at 8:22 PM
Regeneron Pharmaceuticals (REGN) Given a $440.00 Price Target at Credit Suisse GroupRegeneron Pharmaceuticals (REGN) Given a $440.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - February 8 at 7:48 PM
BMO Capital Markets Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)BMO Capital Markets Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)
www.americanbankingnews.com - February 8 at 4:56 PM
Regeneron Pharmaceuticals (REGN) Lowered to Neutral at BTIG ResearchRegeneron Pharmaceuticals (REGN) Lowered to Neutral at BTIG Research
www.americanbankingnews.com - February 8 at 4:22 PM
Regeneron posts 31 percent drop in quarterly profit - ReutersRegeneron posts 31 percent drop in quarterly profit - Reuters
www.reuters.com - February 8 at 3:18 PM
Regeneron Pharmaceuticals Q4 Income Rises - Nasdaq.com - NasdaqRegeneron Pharmaceuticals Q4 Income Rises - Nasdaq.com - Nasdaq
www.nasdaq.com - February 8 at 3:18 PM
Regeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript - Seeking AlphaRegeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 8 at 3:18 PM
Regeneron (REGN) Tops Q4 Earnings & SalesRegeneron (REGN) Tops Q4 Earnings & Sales
finance.yahoo.com - February 8 at 3:18 PM
Regeneron CEO says fears over Eylea "greatly exaggerated"Regeneron CEO says fears over Eylea "greatly exaggerated"
finance.yahoo.com - February 8 at 3:18 PM
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales GrowRegeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
finance.yahoo.com - February 8 at 3:18 PM
Regeneron Dips In Sympathy With Biotechs Despite Quarterly BeatRegeneron Dips In Sympathy With Biotechs Despite Quarterly Beat
finance.yahoo.com - February 8 at 3:18 PM
Amgen’s Repatha and Blincyto: How They Did in 3Q17Amgen’s Repatha and Blincyto: How They Did in 3Q17
finance.yahoo.com - February 8 at 3:18 PM
Regeneron Pharmaceuticals (REGN) Issues Quarterly  Earnings ResultsRegeneron Pharmaceuticals (REGN) Issues Quarterly Earnings Results
www.americanbankingnews.com - February 8 at 11:16 AM
Sanofi, Regeneron Dip As Eczema Drug Dupixent Lags In EuropeSanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europe
finance.yahoo.com - February 8 at 5:28 AM
Sanofi (SNY) Q4 2017 Earnings Conference Call TranscriptSanofi (SNY) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - February 8 at 5:28 AM
Regeneron Pharmaceuticals (REGN) Rating Reiterated by Canaccord GenuityRegeneron Pharmaceuticals (REGN) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - February 8 at 12:14 AM
Regeneron Pharmaceuticals (REGN) Given Hold Rating at CowenRegeneron Pharmaceuticals (REGN) Given Hold Rating at Cowen
www.americanbankingnews.com - February 8 at 12:14 AM

SEC Filings

Regeneron Pharmaceuticals (NASDAQ:REGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regeneron Pharmaceuticals (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regeneron Pharmaceuticals (NASDAQ REGN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.